Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 21, 2013
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer
A J Armstrong, M Häggman, W M Stadler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
A J Armstrong, P Lin, C S Higano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
J N Graff, G Baciarello, A J Armstrong, et al.
Oncogene
|
January 12, 2016
Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways
J A Somarelli, D Schaeffer, M S Marengo, et al.
Prostate Cancer and Prostatic Diseases
|
January 13, 2016
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy
A J Armstrong, S Halabi, P Healy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2021
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
H I Scher, A J Armstrong, J D Schonhoft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2024
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
D E Rathkopf, M R Patel, A D Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88]
D E Rathkopf, M R Patel, A D Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 2017
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet
A J Armstrong, E S Antonarakis, M-E Taplin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 17, 2023
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels
K T Helzer, M N Sharifi, J M Sperger, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 21, 2013
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer
A J Armstrong, M Häggman, W M Stadler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
A J Armstrong, P Lin, C S Higano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
J N Graff, G Baciarello, A J Armstrong, et al.
Oncogene
|
January 12, 2016
Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways
J A Somarelli, D Schaeffer, M S Marengo, et al.
Prostate Cancer and Prostatic Diseases
|
January 13, 2016
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy
A J Armstrong, S Halabi, P Healy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2021
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
H I Scher, A J Armstrong, J D Schonhoft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2024
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
D E Rathkopf, M R Patel, A D Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88]
D E Rathkopf, M R Patel, A D Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 2017
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet
A J Armstrong, E S Antonarakis, M-E Taplin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 17, 2023
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels
K T Helzer, M N Sharifi, J M Sperger, et al.
Page
of 3